GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Francisco Partners Iv, L.P. also recently made the following trade(s):
- On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The stock was sold at an average price of $3.44, for a total value of $437,819.12.
- On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
- On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $961,509.50.
- On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
- On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.
GoodRx Stock Performance
GoodRx stock traded up $0.18 during mid-day trading on Wednesday, reaching $3.65. 3,534,816 shares of the company’s stock were exchanged, compared to its average volume of 1,909,305. The business’s fifty day simple moving average is $3.18 and its 200 day simple moving average is $2.66. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx Holdings, Inc. has a one year low of $1.77 and a one year high of $5.81. The firm has a market capitalization of $1.25 billion, a PE ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on GDRX. Citigroup boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Barclays upped their price objective on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th. UBS Group increased their price objective on GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a report on Thursday, August 13th. Finally, TD Cowen raised their target price on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.23.
Read Our Latest Research Report on GDRX
Institutional Trading of GoodRx
Hedge funds and other institutional investors have recently modified their holdings of the business. Prescott Group Capital Management L.L.C. purchased a new position in GoodRx in the 4th quarter valued at approximately $4,812,000. Technology Crossover Management X Ltd. purchased a new stake in shares of GoodRx during the second quarter worth $4,762,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of GoodRx by 10,242.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock worth $4,072,000 after acquiring an additional 1,488,137 shares during the period. California State Teachers Retirement System boosted its holdings in shares of GoodRx by 192.6% in the second quarter. California State Teachers Retirement System now owns 1,684,431 shares of the company’s stock worth $4,851,000 after acquiring an additional 1,108,766 shares during the period. Finally, AQR Capital Management LLC grew its position in shares of GoodRx by 188.0% in the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock valued at $3,140,000 after purchasing an additional 756,209 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.
About GoodRx
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Recommended Stories
- Five stocks we like better than GoodRx
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
